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Implantable cardioverter-deﬁbrillators (ICDs) for secondary
prevention of sudden cardiac death are increasingly indicated
in patients with congenital heart disease (CHD).1 Children
with CHD present unique challenges for the implantation of
traditional ICDs owing to both cardiac and venous anatomy
and patient size. Novel ICD systems previously described for
small children with CHD in whom a traditional ICD cannot
be implanted include a generator inserted abdominally with a
subcutaneous array electrode placed in the thorax.2 This
technique required the placement of a transvenous or
epicardial pacing and sensing lead. Others have used a
transvenous design ICD lead placed on either the epicardium
or subcutaneous tissue.1 In 2012, an entirely subcutaneous
implantable cardioverter-deﬁbrillator (S-ICD) was approved
for use in the United States by the Food and Drug
Administration after a decade of clinical testing.3 The
S-ICD system (Cameron Health, Inc, San Clemente, CA)
is composed of a pulse generator and a subcutaneous lead
that functions as a sensing lead and a deﬁbrillation coil. The
pulse generator is typically inserted in a subcutaneous pocket
over the left lateral chest wall, and the lead is positioned left
of the sternal border. This system requires no chest entry and
no venous access for sensing leads, making it ideally suited
for patients with complex anatomy related to CHD, those
with active infections, and young patients who will require
the device for many years. To date, the S-ICD system hasKEYWORDS Subcutaneous implantable cardioverter-deﬁbrillator; Congenital
heart disease; Hypoplastic left heart syndrome; Ventricular ﬁbrillation
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34 kg.4 We describe the implantation of the S-ICD in a 3-
year-old boy born with hypoplastic left heart syndrome
(HLHS) for ventricular ﬁbrillatory arrest.
Case report
This child was born with HLHS with intact atrial septum,
requiring an atrial septostomy and atrial septal stent at birth.
At 5 days of age, he underwent stage 1 palliation with the
Norwood procedure and right ventricle to pulmonary artery
(RV-PA) shunt. This was unfortunately complicated by a
pulmonary artery pseudoaneurysm, requiring revision of the
RV-PA shunt in his ﬁfth week of life. Because of pulmonary
artery hypoplasia with multilevel branch pulmonary stenosis,
he underwent complex pulmonary arterioplasty before bidir-
ectional cavopulmonary anastomosis. He has now under-
gone 4 sternotomies and is awaiting stage 3 palliation
for HLHS.
A year after his bidirectional Glenn and while in his
normal state of health, this patient complained of sudden
onset of abdominal pain and became unresponsive. Cardio-
pulmonary resuscitation was initiated, and he was deﬁbril-
lated for polymorphic ventricular tachycardia (VT) by ﬁrst
responders (Figure 1). He was wearing an event monitor at
the time because of several unexplained syncopal episodes in
the preceding 6 weeks. Rhythm strips from this event
showed supraventricular tachycardia and sinus tachycardia
with a premature ventricular contraction occurring on a
T-wave–initiating polymorphic VT. An electrophysiology
study showed no inducible supraventricular tachycardia or
VT, and cardiac catheterization was nondiagnostic for a
reversible cause of this event. He was, therefore, referred for
an ICD.
Because of his altered venous anatomy after bidirectional
Glenn and his size, implanting a transvenous ICD system
was not possible. An epicardial ICD was considered, but we
would have had to accept the risk of redo sternotomy orpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.01.016
Figure 2 The patient’s chest demonstrating a sternal length shorter than
the 14-cm proprietary mapping ruler for the subcutaneous implantable
cardioverter-deﬁbrillator.
KEY TEACHING POINTS
 The need for implantable cardioverter-deﬁbrillators
in patients with congenital heart disease for
secondary prevention of sudden cardiac death will
likely increase over time.
 Patients with congenital heart disease frequently
have multiple cardiac operations and abnormal
vascular connections, complicating the placement
of an implantable cardioverter-deﬁbrillator.
 The subcutaneous implantable cardioverter-
deﬁbrillator provides another option in patients
with congenital heart disease who do not have
normal cardiac anatomy and have been subject to
previous operations. Alternate conﬁgurations of
the generator and coil may be necessary in small
patients.
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considering the options, we elected to attempt the placement
of an S-ICD.
Procedure
Careful consideration was given to appropriate placement of
the generator and lead for this system. Because of the
patient’s small size (13.5 kg), the recommended left thoracic
subcutaneous placement of the generator was not feasible
because it would have been less than the necessary 14 cm
from the sensing electrodes on the lead (Figure 2). We
determined that the least obtrusive location for the generator
would likely be retroperitoneal in the left ﬂank. To create
adequate sensing and deﬁbrillation vectors, the lead was best
oriented vertically over the right chest just medial to the
anterior axillary line. Before implantation the chest was
mapped with surface leads and appropriate sensing was
obtained at this location on the right chest.
A left subcostal incision was made 6 cm in length. After
dividing the muscles of the abdominal wall, the peritoneum
was reﬂected in a medial direction and a retroperitoneal
pocket was created such that the device would be located in
the iliac fossa and extend to the subcostal region. The
disposable tunneling device was then used to create a
subcutaneous tunnel for the lead from a right subcostal
counter incision to the abdominal pocket. In a similar
fashion, the lead was tunneled from the right subcostal
incision to a third incision below the clavicle just medial toFigure 1 Rhythm strip showing polymorphic ventricular tachycardia with
return of normal sinus rhythm after deﬁbrillation.the anterior axillary line. The tip of the lead was ﬁxed to the
pectoral fascia at this infraclavicular location, and the
midportion of the lead was ﬁxed to the abdominal fascia in
the right subcostal region. The lead was then attached to the
generator, which was inserted into the retroperitoneal pocket.
Each incision was then closed in multiple layers (Figure 3).
After implantation, 1 induction of ventricular ﬁbrillation
was performed with successful deﬁbrillation using 80 J.
Shock impedance was 81 Ω, and time to therapy was 19
seconds.Discussion
To our knowledge, this is the ﬁrst documented ventricular
ﬁbrillatory arrest in a patient with HLHS and history of an
RV-PA shunt with stage I Norwood repair between stages II
and III of palliation. Ventricular arrhythmias and sudden
death as a consequence of ventriculotomy has been a critique
of the Sano modiﬁcation of the Norwood repair despite the 1-
year survival beneﬁt of the RV-PA shunt shown by the
randomized multicenter single ventricle reconstruction trial.5
The arrhythmogenic focus in the case of an RV-PA shunt is
thought to be the ﬁbrosis and scar related to the right
ventriculotomy, with a substrate similar to patients with
tetralogy of Fallot, in whom ventricular arrhythmias and
sudden death are clearly documented.6,7 Only 1 study has
shown increased postoperative arrhythmias with the RV-PA
shunt compared with the modiﬁed Blalock-Taussig shunt,8
but ventricular arrhythmias were rare in that study and there
Figure 3 Plain radiograph after the implantation of subcutaneous
implantable cardioverter-deﬁbrillator, with the left-sided retroperitoneal
generator and the subcutaneous lead overlying the right chest wall.
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techniques. Similarly, documented instances of VT or
ventricular ﬁbrillation are low in the few studies that have
reported arrhythmias in this patient population, making
comparisons of these 2 shunt types and the association of
VT/ventricular ﬁbrillation difﬁcult.9,10 Although the rate of
interstage sudden cardiac death at home for HLHS has been
shown to be as high as 42%, the effect of the RV-PA shunt
was not studied in that series.11
As the RV-PA shunt is increasingly used in HLHS for
stage I shunt, interstage and late ventricular arrhythmias in
these patients may become more frequently observed. Thus,
the need for ICD therapy would also be likely to increase.
This case illustrates the complexity of delivering ICD
therapy in patients with HLHS and other CHD palliated by
the 3-stage approach, which ultimately reroutes the systemic
venous return away from the heart and directly to the
pulmonary arteries. Therefore, the transvenous approach to
the heart is not an option. All the previously described
approaches require an epicardial sensing electrode placed
directly on a ventricle.1,2
Because our patient had undergone 4 previous sternoto-
mies with the need for a ﬁfth sternotomy for stage 3
palliation, the possibility of sternotomy or even a limited
thoracotomy was considered high risk and undesirable for
long-term procedural success. Knowing that epicardial
systems carry the increased risk of failure,12,13 an epicardial
approach, even with a subcutaneous array, could potentially
lead to further sternotomies or thoracotomies. In addition to
the advantage of extrathoracic implantation offered by this
system, a single case series of S-ICD implantation in children
and adolescents observed a lower rate of reoperation andinappropriate therapy with the S-ICD compared with trans-
venous ICD systems.14 For these reasons, the S-ICD was the
best option for our patient.
However, the patient’s small size posed technical chal-
lenges that required deviation from the manufacturer’s
recommended approach. The youngest patient previously
described receiving the S-ICD was 10 years old and the
lowest weight was 34 kg.14 Our patient was 13.5 kg with
minimal subcutaneous fat. The risk of generator erosion was
judged to be high, especially considering the dimensions of
the generator, 69.9 cm3 and 145 g, compared with the
dimensions of a standard single-lead ICD system, 30.5 cm3
and 72 g (Incepta E160, Boston Scientiﬁc, Dublin, Ireland).
Ultimately, retroperitoneal generator placement, which is the
standard approach of our team in small infants with
epicardial pacemakers,15 was considered the lowest risk of
generator erosion.
With the R-wave sensing based entirely on the vector of
the 2 cutaneous electrodes to the generator, the potential for
T-wave oversensing and inappropriate shocks with this
atypical conﬁguration was a signiﬁcant concern. Therefore,
before implantation, the potential vectors were re-created
with skin electrodes in different location on the patient’s skin
and with different heart rates and postures to mimic the
vectors of implant. This was further limited by the 14-cm
length of the coil, which ultimately required a position more
lateral to the sternum than recommended, to provide a
shocking vector from the coil to the generator and to avoid
the sternum for future sternotomies.
Conclusion
We report a life-threatening ventricular arrhythmia in a 3-
year-old boy weighing 13.5 kg with HLHS after RV-PA
shunt creation, in whom the implantation of the S-ICD was
successful with the placement of a retroperitoneal generator.
The S-ICD is a promising option for patients with HLHS in
whom transvenous endocardial systems are complicated by
systemic venous discontinuity with the ventricle and in
whom epicardial systems are complicated by multiple
previous sternotomies and small patient size, although
innovative conﬁgurations may be necessary.
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